Dialogue Interview丨Dr. Jacob George & Dr. Xiaolong Qi discuss frontier hotspots of Metabolic Associated Fatty Liver Disease
The 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2024) was held in Kyoto, Japan from March 27 to 31, 2024. Metabolic-associated fatty liver disease (MAFLD) was one of the hot topics in the congress. MAFLD has become a common chronic liver disease worldwide and is caused by metabolic dysfunction. MAFLD is the main reason for the surge in the incidence of liver cirrhosis, liver failure, and liver cancer. In recent years, the incidence of MAFLD has been rising due to changes in lifestyles with high calorie, energy-dense diets and lack of exercise. During the conference, Dr. Jacob George from Westmead Hospital, University of Sydney, Australia, and Dr. Xiaolong Qi, founder of CHESS and Zhongda Hospital, School of Medicine, Southeast University, China, had in-depth exchanges and discussions on the prevalence trends, diagnosis and treatment progress, and comprehensive management of MAFLD. Hepatology Digest hereby reports.